16-29814466-TG-GC
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PVS1PM2
The NM_145239.3(PRRT2):c.1012+2T>C variant causes a splice donor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_145239.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_145239.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PRRT2 | MANE Select | c.1012+2T>C | splice_donor intron | N/A | NP_660282.2 | Q7Z6L0-1 | |||
| PRRT2 | c.1014T>C | p.Gly338Gly | synonymous | Exon 3 of 3 | NP_001243371.1 | Q7Z6L0-2 | |||
| PRRT2 | c.1014T>C | p.Gly338Gly | synonymous | Exon 3 of 3 | NP_001425050.1 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PRRT2 | TSL:1 MANE Select | c.1012+2T>C | splice_donor intron | N/A | ENSP00000351608.7 | Q7Z6L0-1 | |||
| ENSG00000280893 | TSL:5 | n.1001+2T>C | splice_donor intron | N/A | ENSP00000476774.2 | A0A0G2JLL6 | |||
| PRRT2 | TSL:2 | c.1014T>C | p.Gly338Gly | synonymous | Exon 3 of 3 | ENSP00000456226.1 | Q7Z6L0-2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 32
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.